Literature DB >> 22605912

Brilinta™ (ticagrelor) Tablets: A P2Y(12) platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS).

.   

Abstract

Entities:  

Year:  2012        PMID： 22605912      PMCID： PMC3353491     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  3 in total

1.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association.

Authors:  Véronique L Roger; Alan S Go; Donald M Lloyd-Jones; Robert J Adams; Jarett D Berry; Todd M Brown; Mercedes R Carnethon; Shifan Dai; Giovanni de Simone; Earl S Ford; Caroline S Fox; Heather J Fullerton; Cathleen Gillespie; Kurt J Greenlund; Susan M Hailpern; John A Heit; P Michael Ho; Virginia J Howard; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Diane M Makuc; Gregory M Marcus; Ariane Marelli; David B Matchar; Mary M McDermott; James B Meigs; Claudia S Moy; Dariush Mozaffarian; Michael E Mussolino; Graham Nichol; Nina P Paynter; Wayne D Rosamond; Paul D Sorlie; Randall S Stafford; Tanya N Turan; Melanie B Turner; Nathan D Wong; Judith Wylie-Rosett
Journal:  Circulation       Date:  2010-12-15       Impact factor: 29.690

2.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes.

Authors:  Lars Wallentin; Richard C Becker; Andrzej Budaj; Christopher P Cannon; Håkan Emanuelsson; Claes Held; Jay Horrow; Steen Husted; Stefan James; Hugo Katus; Kenneth W Mahaffey; Benjamin M Scirica; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert A Harrington; Anneli Freij; Mona Thorsén
Journal:  N Engl J Med       Date:  2009-08-30       Impact factor: 91.245

3.  Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.

Authors:  Stefan James; Axel Akerblom; Christopher P Cannon; Håkan Emanuelsson; Steen Husted; Hugo Katus; Allan Skene; Philippe Gabriel Steg; Robert F Storey; Robert Harrington; Richard Becker; Lars Wallentin
Journal:  Am Heart J       Date:  2009-04       Impact factor: 4.749
  3 in total
  2 in total

Review 1.  Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose.

Authors:  Tarun Girotra; Forrest Lowe; Wuwei Feng; Bruce Ovbiagele
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

2.  A Rare Case of Delayed Onset Multi-Drug Interaction Resulting in Rhabdomyolysis in a 66-Year-Old Male.

Authors:  Harmony Osborn; Daniel Grossman; Smriti Kochhar; Anish Kanukuntla; Priyaranjan Kata; Pramil Cheriyath
Journal:  Cureus       Date:  2021-11-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.